According to the Complaint, Momo operates a mobile-based social and entertainment platform in the PRC.

According to the Complaint, Jumia characterizes itself as the leading pan-African e-commerce platform, which it represents to consist of: (i) a marketplace that connects sellers with consumers; (ii) a package shipment and delivery service; and (iii) a payment service.

According to the Complaint, Nabriva Therapeutics plc is a biopharmaceutical company that purports to develop novel antiinfective agents to treat serious infections. One of the Company's product candidates is CONTEPO, an epoxide antibiotic developed by Zavante Therapeutics ("Zavante"), which the Company acquired in July 2018.

According to the Complaint, Papa Murphy’s is a franchisor and operator of the largest “Take ‘n’ Bake” pizza brand in the United States, selling hand-crafted, fresh pizzas for customers to bake at home.

According to the Complaint, Indivior together with its subsidiaries, develops, manufactures, and sells buprenorphine-based prescription drugs for the treatment of opioid dependence. The Company’s product pipeline focuses on treating opioid use disorder, alcohol use disorder, opiate overdose, and schizophrenia.

According to the Complaint, APYX Medical Corporation is a medical technology company that purportedly develops J-Plasma, a plasma-based surgical product for cutting, coagulation and ablation of soft tissue. The Company markets and sells J-Plasma under the brand name Renuvion Cosmetic Technology. The Company claims that it has developed J-Plasma/Renuvion for use in dermal resurfacing procedures. Apyx was formerly known as Bovie Medical Corporation, and its stock traded on the New York Stock Exchange ("NYSE") under the symbol "BVX" until January 1, 2019.

According to the Complaint, Taronis purportedly operates as an energy company that offers technology solutions to create, process, and produce hydrogen-based fuel through the gasification of carb-rich liquids. Taronis formerly operated under the name of MagneGas Applied Technology Solutions, Inc.

According to the Complaint, Teligent researches, develops, produces, supplies, and sells generic pharmaceutical products.

According to the Complaint, Amyris purports to be an industrial biotechnology company that manufactures and
sells natural, sustainably-sourced products in health and wellness, clean beauty, and flavor and fragrance markets.

According to the law firm press release, the complaint alleges that the Offering Documents failed to disclose that: (1) a shortage of trucks was negatively impacting U.S. Xpress's dedicated division; (2) (a) certain shipping patterns had been performing differently than expected and, as a result, (b) utilization and driver retention and hiring were being negatively affected, and as a result, (c) U.S. Xpress's dedicated accounts, including one large account, were being negatively impacted; and as a result, (d) U.S. Xpress's OTR division was providing continued support to the dedicated division; (3) (a) U.S. Xpress failed to stay informed regarding two large liability events; and as a result (b) U.S. Xpress's insurance claim expense was understated; and (4) U.S. Xpress's cost per mile for driver wages and independent contractors was exceeding the Company's internal expectations.

Plaintiff's law firm issued a press release on March 29, 2019 announcing the filing of the lawsuit. The Complaint alleges that during the Class Period, Defendants were engaged in an undisclosed pump and dump scheme that manipulated and artificially inflated the price of First Choice common stock, and failed to disclose their involvement, rendering certain of their public statements materially misleading.

According to the Complaint, Nutanix "provides a leading enterprise cloud platform that powers many of the world's business applications and end user services by providing software solutions that digitize traditional silos of enterprise computing."

According to the Complaint, American Renal purports to operate as a dialysis services provider in the United States.

According to the Complaint, Healthcare Services Group, Inc. engages in the management, administrative, and operating services to the housekeeping, laundry, linen, facility maintenance, and dietary service departments to nursing homes, retirement complexes, rehabilitation centers, and hospitals in the United States.

According to the Complaint, United Microelectronics Corporation ("UMC" or the "Company") provides semiconductor wafer foundry solutions.

According to the Complaint, Corcept is a pharmaceutical company that purports to develop medications to treat
severe metabolic, oncologic, and psychiatric disorders by modulating the effect of cortisol. Korlym is the Company's drug that has been approved by the FDA to treat hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome.

According to the Complaint, Stamps.com is a provider of Internet-based mailing and shipping solutions in the United States. Under the Stamps.com and Endicia brands, Stamps.com customers use USPS solutions to mail and ship a variety of mail pieces and packages through the USPS and customers using Stamps.com solutions receive discounted postage rates compared to USPS.com and USPS retail locations on certain mail pieces.

According to the Complaint, Diplomat purports to operate as an independent specialty pharmacy in the United States.

According to the Complaint, Conduent was formed effective December 31, 2016 from a collection of businesses within the Xerox Corporation. Conduent was spun-off to Xerox shareholders in a ratio of one Conduent share for every five Xerox shares owned. Conduent's primary business is to run operations for clients, such as toll-booth collections.

According to the law firm press release, the complaint alleges that Spectrum misrepresented and failed to disclose that: (i) Spectrum had been self-inflicting the operational issues at its Ohio and Kansas facilities; (ii) these operational issues were, in fact, recurring in nature; (iii) these operational issues would continuously impact production, shipping levels and sales; and (iv) as a result of the foregoing, the Company's financial statements were materially false and misleading at all relevant times.